美國

證券交易委員會

華盛頓特區，20549

表格8-K

當前報告

根據 1934年證券交易法 第13或15（d）條

報告日期(最早報告事件日期)： 2024年3月4日

AKARI 治療，PLC

(註冊人在其章程中規定的確切名稱 )

註冊人的電話號碼，包括區號：（929） 274—7510

不適用
(前姓名或前地址，如果自上次報告後更改)

如果申請表8-K 旨在同時滿足註冊人根據下列任何一項規定的備案義務，請勾選下面相應的框：

根據該法第12(B)款登記的證券：

*交易，但僅限於與美國存托股份(美國存托股份)相關的交易。

用複選標記表示註冊人 是否是1933年《證券法》規則第405條(本章230.405節)或1934年《證券交易法》規則第12b-2條(本章第240.12b-2節)所界定的新興成長型公司。

新興的成長型公司？

如果 是一家新興成長型公司，請用複選標記表示註冊人是否已選擇不使用延長的過渡期來遵守根據《交易所法案》第13(A)節提供的任何新的或修訂的財務會計準則。？

合併協議

2024年3月4日，Akari治療公司(一家在英格蘭和威爾士註冊成立的上市公司)與Peak Bio，Inc.(“Peak Bio”)和Pegasus Merger Sub，Inc.，特拉華州一家公司和Akari的全資子公司(“Merge Sub”)簽訂了一項合併協議和計劃(“合併協議”)，根據協議的條款和條件，合併子公司將與Peak Bio，Inc.(“合併”)合併。Peak Bio作為Akari的全資子公司在合併後存活了下來。

根據合併協議，並根據 條款及受制於該等條件，於合併生效時(“生效時間”)，各發行 及已發行的公司普通股，每股面值0.0001美元(“匹克普通股”)(不包括(X)股匹克生物作為庫存股持有的匹克普通股股份，或由Akari、合併子公司或任何直接或間接全資附屬公司擁有的匹克普通股股份，及(Y)股異議股份(定義見合併協議)，將轉換為權利 以收取相當於若干Akari普通股的Akari美國存托股份(“Akari ADS”)，面值為每股0.0001美元(“Akari普通股”)，相當於根據合併 協議計算的交換比率(“交換比率”)，根據存款協議(定義見合併協議)繳存所需數目的Akari普通股而正式及有效發行的每股該等股份。交換比率將按交換比率計算 ，以作為匹克普通股的合併代價而發行的Akari ADS股份總數預計於發行時約為Akari ADS已發行股份的50%(前提是該比率將就Akari及Peak Bio各自於預期完成合並前一個營業日的營業時間結束時根據合併協議釐定的現金淨值作出若干調整)。合併協議規定，在某些情況下，在合併完成後，可向匹克普通股的股份持有人額外發行 張美國存託憑證，相當於根據合併協議計算的 交換比率(“額外交換比率”)。

於生效時間，每份購買Peak Bio股本的權證(“Peak認股權證”)將於緊接生效時間前轉換為 ，並可交換為由Akari釐定的購買若干Akari普通股或Akari ADS的認股權證(每個為“經調整 認股權證”)，其條款及條件與緊接生效時間前適用於該等峯值認股權證的條款及條件大致相若，但(I)因合併協議擬進行的交易而無法生效的條款除外，(Ii)如以下句子所述及(Iii)根據適用法律(定義見合併協議)對經調整認股權證的條款作出必要的修訂。受每份調整認股權證約束的Akari普通股(或Akari ADS相關的Akari普通股數量 )將等於緊接生效時間前該峯值認股權證行使時可發行的峯值普通股數量乘以兑換比率， 任何零碎的Akari普通股或Akari ADS向下舍入為最接近的完整Akari普通股或Akari美國存托股份(視情況而定)， 以及每股Akari普通股(或每股Akari相關ADS，如適用) 相關經調整認股權證將等於緊接生效時間前該等峯值認股權證的行使價除以兑換比率。經調整認股權證的授出將自生效時間起生效，或在考慮到母公司的行政程序後，在合理可行的情況下儘快生效。經調整認股權證將進一步調整(如適用) ，以落實額外兑換比率的影響。

收購匹克普通股 股票的每一項期權(“匹剋期權”)在緊接生效時間之前尚未行使且未行使，無論是否已歸屬，都將被假定並轉換為購買若干Akari普通股或Akari美國存託憑證的期權，由Akari 決定(每個，“調整後期權”)。受調整後期權約束的阿卡里普通股數量(或相關的阿卡里普通股數量，視情況而定)將等於(I)在緊接生效時間之前受該峯值期權約束的普通股總數乘以(Ii)兑換比率，任何 分數的阿卡里普通股或阿卡里美國存託憑證向下舍入為最接近的完整阿卡里普通股或阿卡里美國存托股份(視情況適用)的乘積。和 每股經調整期權的行權價將等於緊接生效時間之前該Peak期權的行權價除以兑換比率。調整後的期權將進一步調整(如果適用)，以實現額外匯率比率的影響 。

合併協議包含由Akari、Peak Bio和Merger Sub提供的慣例陳述、 擔保和契諾。合併協議還包含慣例的成交前契約， 包括雙方在合併完成前各自開展各自業務的契約。此外，各方已同意利用各自在商業上合理的努力，採取一切必要、適當或可取的行動來完成合並和合並協議預期的其他交易，包括在合理可行的情況下儘快就合併提交任何所需的監管備案文件，但Akari和Peak Bio均不需要剝離Peak Bio的任何資產或業務。Akari或其各自的任何附屬公司和子公司。

合併協議 還規定，從合併生效時間和合並協議終止之日起，Akari和Peak生物各自在向第三方徵求收購建議、向第三方提供信息以及與第三方就收購建議進行討論的能力方面受到某些限制，但符合慣例的例外情況除外。此外， Akari和Peak Bio的董事會都必須建議各自的股東或股東投票贊成合併，但有更高提議的例外情況和其他未能實施建議變更的情況 將與董事會的受託責任不一致。

合併的完成取決於各種 條件，其中包括：(I)Peak Bio股東批准合併協議和合並，(Ii)Akari的股東授權Akari董事會分配與合併相關的所有Akari普通股 (由Akari ADS代表)，(Iii)沒有任何禁止完成合並的法律或命令，(Iv)Akari採用S-4表格的註冊聲明(將與合併相關發佈)已宣佈生效，(V)可發行給匹克生物股東的美國存託憑證已獲授權在納斯達克上市，(Vi)另一方陳述和擔保的準確性(受合併協議中規定的某些重大標準的約束)，(Vii)另一方在所有實質性方面遵守該另一方在合併協議下的義務的情況。(Viii)在沒有對另一方造成重大不利影響的情況下，(Ix)另一方的現金淨值大於負13,500,000美元，以及(X)根據合併協議的定義，管道投資(Br)應在交易完成時同時完成，且僅以此為條件，並應為Akari帶來至少10,000,000美元的淨收益。

在某些情況下，阿卡里或匹克生物可終止合併協議 如果(I)合併未於2024年9月4日前完成，(Ii)另一方董事會撤回、修改或修改其建議，以支持合併協議所設想的交易，或批准或建議替代交易，或(Iii)阿卡里或匹克生物董事會， 根據適用情況，決定在獲得阿卡里 美國存托股份發行或合併批准之前，就更高提議達成最終協議，從Akari的股東或Peak Bio的股東(視情況而定)。合併協議 還規定，在合併協議、Akari或Peak Bio(視情況而定)所述的特定終止情況下， 將被要求支付相當於300,000美元的終止費，並向另一方償還與交易相關的費用，最高可達 150萬美元。

其他 信息

以上是對合並和合並協議的一般描述；它並不聲稱是完整的，並通過參考合併協議進行了整體限定， 該合併協議作為本8-K表格的附件2.1附於本報告，並通過引用併入本文。

The Merger Agreement, which is attached as Exhibit 2.1, has been described above to provide investors and Akari shareholders with information regarding the terms of the Merger Agreement and is not intended to modify or supplement any factual disclosures about Akari, Merger Sub or Peak Bio or any of their respective affiliates. The representations, warranties and covenants contained in the Merger Agreement were made only for the purposes of the Merger Agreement, were made as of specific dates, were made solely for the benefit of the parties to the Merger Agreement and may not have been intended to be statements of fact, but rather, as a method of allocating risk and governing the contractual rights and relationships among the parties to the Merger Agreement. In addition, such representations, warranties and covenants may have been qualified by certain disclosures not reflected in the text of the Merger Agreement and may apply standards of materiality and other qualifications and limitations in a way that is different from what may be viewed as material by Akari’s shareholders or Peak Bio’s stockholders. In reviewing the representations, warranties and covenants contained in the Merger Agreement or any descriptions thereof in this summary, it is important to bear in mind that such representations, warranties and covenants or any descriptions were not intended by the parties to the Merger Agreement to be characterizations of the actual state of facts or conditions of Akari, Merger Sub or Peak Bio or any of their respective affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in public disclosures. For the foregoing reasons, the representations, warranties and covenants or any descriptions of those provisions should not be read alone and should instead be read in conjunction with the other information contained in the reports, statements and filings that Akari and Peak Bio publicly file with the SEC.

投票協議

與 合併協議同時，Akari和Peak Bio與Akari的某些 股東（“Akari股東”）和Peak Bio的某些股東（“Peak股東” ，以及Akari股東一起稱為“支持股東”）訂立了投票和支持協議（“投票協議”）。支持持有人已同意（其中包括）根據Akari和Peak Bio各自董事會的建議，投票支持合併協議和合並或發行Akari普通股（如適用）。

截至2024年3月1日，Akari股東實益擁有合計約39.51%的已發行Akari普通股。截至 二零二四年三月一日，Peak股東實益擁有Peak普通股 合共約39. 3%的已發行股份。

投票協議 將於（a）生效時間、（b）收到支持持有人的批准（如適用）以及（c）合併協議有效終止的日期和時間（以最早日期為準）終止。

上述表決協議 的描述並不完整，而是受表決協議形式的約束，並受表決協議形式的全部限制， 的形式作為附件10.1和10.2提交，並通過引用併入本文。

2024年3月5日，Akari和Peak Bio發佈聯合新聞稿，宣佈執行合併協議。新聞稿作為附件99.1附於本協議。

根據本第7.01項（ 包括附件99.1）提供的信息不應被視為根據1934年《證券交易法》第18條（ 修訂）的目的“已提交（《交易法》），或以其他方式受該條下的法律責任約束，且不得視為 以引用的方式納入根據1933年證券法或交易法提交的任何文件中，除非在此類文件中以特定的引用方式明確規定。此外，附件99.1包含旨在作為"前瞻性陳述"的陳述， 受此類附件中所列前瞻性陳述的警示性陳述的約束。

(D)展品。

首席執行官

This current report relates to the proposed transaction pursuant to the terms of the Merger Agreement, by and among Akari, Pegasus Merger Sub, Inc., and Peak Bio and includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act, about the proposed transaction between Peak Bio and Akari and the operations of the combined company that involve risks and uncertainties relating to future events and the future performance of Akari and Peak Bio. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding: the Merger and related matters, including, but not limited to, satisfaction of closing conditions to the proposed transaction, prospective performance and opportunities with respect to Akari or Peak Bio, post-closing operations and the outlook for the companies’ businesses; Akari’s, Peak Bio’s or the combined company’s targets, plans, objectives or goals for future operations, including those related to Akari’s and Peak Bio’s product candidates, research and development, product candidate introductions and product candidate approvals as well as cooperation in relation thereto; projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures; future economic performance, future actions and outcome of contingencies such as legal proceedings; and the assumptions underlying or relating to such statements.

These statements are based on Akari’s and Peak Bio’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the timing for completion of the proposed transaction; uncertainties as to Peak Bio’s and/or Akari’s ability to obtain the approval of Akari’s shareholders or Peak Bio’s stockholders required to consummate the proposed transaction; the possibility that competing offers will be made by third parties; the occurrence of events that may give rise to a right of one or both of Akari and Peak Bio to terminate the Merger Agreement; the possibility that various closing conditions for the proposed transaction may not be satisfied or waived on a timely basis or at all, including the possibility that a governmental entity may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of consents or regulatory approvals or actions, if any; the possibility that the proposed transaction may not be completed in the time frame expected by Akari and Peak Bio, or at all; the risk that Akari and Peak Bio may not realize the anticipated benefits of the proposed transaction in the time frame expected, or at all; the effects of the proposed transaction on relationships with Akari’s or Peak Bio’s employees, business or collaboration partners or governmental entities; the ability to retain and hire key personnel; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction; significant or unexpected costs, charges or expenses resulting from the proposed transaction; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the combined business after the consummation of the proposed transaction; potential negative effects related to this announcement or the consummation of the proposed transaction on the market price of Akari’s American Depositary Shares or Peak Bio’s common stock and/or Akari’s or Peak Bio’s operating or financial results; uncertainties as to the long-term value of Akari’s American Depositary Shares (and the ordinary shares represented thereby), including the dilution caused by Akari’s issuance of additional American Depositary Shares (and the ordinary shares represented thereby) in connection with the proposed transaction; unknown liabilities related to Akari or Peak Bio; the nature, cost and outcome of any litigation and other legal proceedings involving Akari, Peak Bio or their respective directors, including any legal proceedings related to the proposed transaction; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of Akari’s or Peak Bio’s programs or product candidates; risks related to any loss of Akari’s or Peak Bio’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for Akari or Peak Bio’s product candidates, the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by Akari, Peak Bio and/or their respective collaborators or licensees; the extent to which the results from the research and development programs conducted by Akari, Peak Bio, and/or their respective collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of Akari’s or Peak Bio’s product candidates, and the impact of studies (whether conducted by Akari, Peak Bio or others and whether mandated or voluntary) on any of the foregoing; unexpected breaches or terminations with respect to Akari’s or Peak Bios’s material contracts or arrangements; risks related to competition for Akari’s or Peak Bio’s product candidates; Akari’s or Peak Bio’s ability to successfully develop or commercialize Akari’s or Peak Bio’s product candidates; Akari’s, Peak Bio’s, and their collaborators’ abilities to continue to conduct current and future developmental, preclinical and clinical programs; potential exposure to legal proceedings and investigations; risks related to changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing, development or commercialization of any of Akari’s or Peak Bio’s product candidates; unexpected increase in costs and expenses with respect to the potential transaction or Akari’s or Peak Bio’s business or operations; and risks and uncertainties related to epidemics, pandemics or other public health crises and their impact on Akari’s and Peak Bio’s respective businesses, operations, supply chain, patient enrollment and retention, preclinical and clinical trials, strategy, goals and anticipated milestones. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. There can be no assurance that the proposed transaction or any other transaction described above will in fact be consummated in the manner described or at all. A more complete description of these and other material risks can be found in Akari’s and Peak Bios’s respective filings with the U.S. Securities and Exchange Commission (the “SEC”), including each of their Annual Reports on Form 20-F and 10-K, respectively, for the year ended December 31, 2022, subsequent periodic reports, and other documents that may be filed from time to time with the SEC. These risks, as well as other risks associated with the proposed transaction, will be more fully discussed in the joint proxy statement/prospectus that will be included in the registration statement on Form S-4 that will be filed with the SEC in connection with the proposed transaction, which joint proxy statement/prospectus will be mailed or otherwise disseminated to Akari’s shareholders and Peak Bio’s stockholders when it becomes available.

Any forward-looking statements speak only as of the date of this communication and are made based on the current beliefs and judgments of Akari’s and Peak Bio’s management, and the reader is cautioned not to rely on any forward-looking statements made by Akari or Peak Bio. Unless required by law, neither Akari nor Peak Bio is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, including without limitation any financial projection or guidance, whether as a result of new information, future events or otherwise.

No Offer or Solicitation

This current report is not intended to and shall not constitute an offer to subscribe for, buy or sell or the solicitation of an offer to subscribe for, buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of, or offer to sell or buy, securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication is for informational purposes only. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

In connection with the proposed transaction, Akari and Peak Bio expect to file with the SEC a Registration Statement on Form S-4. The Registration Statement on Form S-4 will include a prospectus of Akari and a joint proxy statement of Akari and Peak Bio, and each party may also file other documents regarding the proposed transaction with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY THE REGISTRATION STATEMENT ON FORM S-4, JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN, IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.

You may obtain a free copy of the Registration Statement on Form S-4, joint proxy statement/prospectus and other relevant documents (if and when they become available) that are or will be filed with the SEC for free at the SEC’s website at www.sec.gov. Copies of the documents filed with the SEC by Akari will be available free of charge on Akari’s website at http://investor.akaritx.com/ or by contacting Akari’s Investor Relations Department at http://investor.akaritx.com/investor-resources/contact-us. Copies of the documents filed with the SEC by Peak Bio will be available free of charge on Peak Bio’s website at https://peak-bio.com/investors or by contacting Peak Bio’s Investor Relations Department at https://peak-bio.com/contact.

Participants in the Solicitation

Akari, Peak Bio and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about the directors and executive officers of Akari, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Akari’s Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on May 1, 2023, subsequent quarterly and current reports on Form 10-Q and -K, respectively, and other documents that may be filed from time to time with the SEC. Information about the directors and executive officers of Peak Bio, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in Peak Bio’s proxy statement for its 2022 Special Meeting of Stockholders, which was filed with the SEC on October 19, 2022, the Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on June 29, 2023, subsequent quarterly and current reports on Form 10-Q and Form 8-K, respectively, and other documents that may be filed from time to time with the SEC. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus included in the Registration Statement on Form S-4 and other relevant materials to be filed with the SEC regarding the proposed transaction when such materials become available. Security holders, potential investors and other readers should read the joint proxy statement/prospectus, included in the Registration Statement on Form S-4 carefully when it becomes available before making any voting or investment decision. You may obtain free copies of these documents from Akari or Peak Bio using the sources indicated above.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.